[Observation of systemic adverse reactions by specific immunotherapy and analysis of risk factors in allergic rhinitis]

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Nov 7;52(11):801-805. doi: 10.3760/cma.j.issn.1673-0860.2017.11.001.
[Article in Chinese]

Abstract

Objective: To investigate the systemic adverse effects of specific subcutaneous immunotherapy (SCIT) in patients with allergic rhinitis (AR) and explore the possible risk factors. Methods: A retrospective study was conducted on AR patients who underwent SCIT from January 2014 to January 2017 in Department of Otorhinolaryngology, the First Affiliated Hospital of Chongqing Medical University. For patients with adverse reactions, the detailed medical history during treatment was reviewed. Results: A total of 1608 injections were performed on 102 patients, there were 12 cases / 21 times systemic adverse events, including systemic urticaria, angioedema and Grade Ⅰ systemic adverse reactions. There were 3 cases of grade Ⅳ adverse reactions. Systemic adverse reaction was prone to an initial treatment phase where the dose and concentration of the injection were increasing. Meanwhile, it was more common in young patients aged 20-40 years old and easy to occur in May and June. About the possible risk factors, the most common one was obvious local adverse reactions (17/21), followed by prolonged injection interval (9/21), the recent exposure to a large number of allergens (7/21) and strong positive skin prick results (7/21). Conclusions: The systemic adverse effects, which were induced by SCIT, mainly included systemic urticaria, angioedema and Grade Ⅰ systemic adverse reactions. Systemic adverse reaction was prone to an initial treatment phase where the dose and concentration of the injection were increasing.

目的: 观察变应性鼻炎(allergic rhinitis,AR)患者特异性皮下免疫治疗(subcutaneous immunotherapy,SCIT)的全身不良反应,探寻可能的危险因素。 方法: 对2015年1月至2017年3月在重庆医科大学附属第一医院耳鼻咽喉科行SCIT的AR患者进行回顾性调查,对发生不良反应的患者分析其治疗过程中的详细病史资料。 结果: 在对102例AR患者的1 608次SCIT注射中,共有12例患者发生21次全身不良反应,以全身性荨麻疹、血管性水肿和Ⅰ级全身不良反应为主,另包含3例Ⅳ级不良反应。全身不良反应多发生于注射剂量和浓度逐渐增加的初始治疗阶段及注射的变应原绝对量较大时;多见于20~40岁患者;易发生于5~6月份。在可能诱发全身不良反应的危险因素中,以明显局部不良反应最多见(17/21),其次为注射间隔时间延长(9/21)、近期接触大量变应原(7/21)和皮肤点刺结果强阳性(7/21)。 结论: SCIT诱发的全身不良反应,主要表现为全身性荨麻疹和血管性水肿,以Ⅰ级全身不良反应为主;更易发生于注射剂量和浓度逐渐增加的初始治疗阶段,及注射的变应原绝对量较大时。.

Keywords: Immunotherapy; Rhinitis, allergic; Risk factors.

MeSH terms

  • Adult
  • Age Factors
  • Allergens / adverse effects
  • Desensitization, Immunologic / adverse effects*
  • Humans
  • Injections, Subcutaneous
  • Retrospective Studies
  • Rhinitis, Allergic / therapy*
  • Risk Factors

Substances

  • Allergens